Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer

被引：0
|
作者：
Susanne Taucher
Margaretha Rudas
Robert M. Mader
Michael Gnant
Emanuel Sporn
Peter Dubsky
Sebastian Roka
Thomas Bachleitner
Florian Fitzal
Daniela Kandioler
Catharina Wenzel
Günther G. Steger
Martina Mittlböck
Raimund Jakesz
机构：
[1] Vienna University Medical School,Department of Surgery
[2] Vienna University Medical School,Department of Pathology
[3] Vienna University Medical School,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 82卷
关键词：
breast cancer; core needle biopsy; docetaxel; epirubicin; FISH; HER2/; immunohistochemistry; preoperative treatment; trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background. In primary breast cancer, the expression levels of biological markers relevant to the progression of the disease may be altered by administration of anticancer drugs. Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu.
引用
收藏
页码：207 / 213
页数：6
相关论文
共 50 条
  • [21] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    LABORATORY INVESTIGATION, 2018, 98 : 91 - 91
  • [22] A different yet traditional approach to neoadjuvant treatment of breast cancer: The combination of epirubicin and docetaxel Neoadjuvant epirubicin docetaxel in breast cancer'
    Yuce, Elif
    Karakullukcu, Serdar
    Alandag, Celal
    Bulbul, Hatice
    Saygin, Ismail
    Kavgaci, Halil
    ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, 2023, 14
  • [23] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    BREAST, 2017, 32 : S18 - S18
  • [24] HER2 assessment to define outcomes for breast cancer patients treated with neoadjuvant therapy
    Cheng, Huan
    Bai, Yalai
    Sikov, Willliam
    Sinclair, Natalie
    Abu-Khalaf, Maysa
    Harris, Lyndsay N.
    Rimm, David L.
    CANCER RESEARCH, 2012, 72
  • [25] Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study
    Greil, R.
    Moik, M.
    Reitsamer, R.
    Ressler, S.
    Stoll, M.
    Namberger, K.
    Menzel, C.
    Mlineritsch, B.
    EJSO, 2009, 35 (10): : 1048 - 1054
  • [26] Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
    Heidy Cedeño
    Rafael Araúz
    Fernando Cebamanos
    Idalmis de Torraza
    Ana Porcell
    BMC Cancer, 7 (Suppl 1)
  • [27] Gene Expression Profiling for Therapy Prediction in a Breast Cancer Neoadjuvant Therapy Study Applying Docetaxel/Epirubicin/Cyclophosphamide
    Kemming, D.
    Schlotter, C. M.
    Bosse, U.
    Vogt, U.
    Muhs, H-J
    von der Assen, A.
    Brandt, B. H.
    CANCER RESEARCH, 2009, 69 (24) : 604S - 605S
  • [28] EXPRESSION BY INMUNOHISTOCHEMISTRY OF HER2 NEU ONCOGEN IN DUCTAL INVASIVE BREAST CANCER
    Francisco, Menolascino-Bratta
    Carolina Isabel, Martinez-Garcia
    Jorge Rafael, Uribe
    SALUD ARTE Y CUIDADO, 2012, 5 (02): : 32 - 50
  • [29] HER2/neu in systemic therapy for women with breast cancer:: a systematic review
    Dhesy-Thind, Bindi
    Pritchard, Kathleen I.
    Messersmith, Hans
    O'Malley, Frances
    Elavathil, Leela
    Trudeau, Maureen
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 209 - 229
  • [30] HER2/neu in systemic therapy for women with breast cancer: a systematic review
    Bindi Dhesy-Thind
    Kathleen I. Pritchard
    Hans Messersmith
    Frances O’Malley
    Leela Elavathil
    Maureen Trudeau
    Breast Cancer Research and Treatment, 2008, 109 : 209 - 229
12345